=> d que l26
L1 STR



VAR G1=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L3 STR

Cy—Hy—C═C
1 2 3 4

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 1
GGCAT IS MCY LOQ UNS AT 2
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE
L4 STR

Cy—Hy—C≡C
1 2 3 4

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 1
GGCAT IS MCY LOQ UNS AT 2
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE
L8 3870 SEA FILE=REGISTRY SSS FUL L1 AND (L3 OR L4)

L23 STR



VAR G1=CH3/6/26
VAR G5=H/21/23
VAR G8=H/21
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 21
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 1
GGCAT IS MCY LOQ UNS AT 2
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L24 STR



VAR G1=CH3/6/26
VAR G5=H/21/23
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 21
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 1
GGCAT IS MCY LOQ UNS AT 2
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L26 582 SEA FILE=REGISTRY SUB=L8 SSS FUL L23 OR L24

=> d bib abs hitstr 1-9

L28 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 2000:814466 CAPLUS
DN 133:362714
TI Preparation of cyclic compounds having antagonism against .beta.-beta chemokine receptor (CCR5)
IN Shiraishi, Mitsuru; Baba, Masanori; Seto, Masaki; Kanzaki, Naoyuki; Nishimura, Osamu
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 282 pp.
CODEN: PIXXD2
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000068203	A1	20001116	WO 2000-JP2825	20000428
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001026586	A2	20010130	JP 2000-134249	20000428

PRAI JP 1999-127724 19990507
OS MARPAT 133:362714
GI

Q = 

Q1 = 

Q2 = 

AB Compds. of general formula R1-X1-W-X2-Z1-Z2-R2 or salts thereof [wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or divalent group having 1-4 C atoms in the straight chain moiety; W is a divalent group represented by general formula Q, Q1, or Q2 (wherein A and B are each an optionally substituted five- to seven-membered ring; E1 and E4 are each optionally substituted carbon or N; E2 and E3 are each optionally substituted carbon or N, O, or optionally oxidized S; and a and b are each a single bond or a double bond); X2 is a divalent group constituting a C1-4 straight chain moiety; Z1 is a single bond or a divalent cyclic group; Z2 is a free valency or divalent group having 1-4 C atoms in the straight chain moiety; and R2 is (1) optionally substituted, quaternized, or oxidized amino, (2) optionally substituted N-contg. heterocyclyl optionally contg. S or O and optionally quaternized or oxidized at the N atom, (3) group bonding through S atom, etc.] are prepd. These compds. exhibit preventive and therapeutic effects against HIV infections or AIDS. Thus, chlorination of 7-[(2-propoxybenzyl)oxy]-1,1-dioxo-2,3-dihydro-1-benzothiepin-4-carboxylic acid by SOCl2 in the presence of one drop of DMF at room temp. for 1 h followed by condensation with 4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]aniline in the presence of Et3N in THF at room temp. for 2 days gave N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-7-[(2-propoxybenzyl)oxy]-1,1-dioxo-2,3-dihydro-1-benzothiepin-4-carboxamide (I). I in vitro inhibited the binding of 125I-RANTES to recombinant CCR5 receptor by 98%. A capsule

and a tablet formulation contg. I were prepd.

IT **307301-89-9P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of cyclic compds. having antagonism against CCR 5 receptor for preventives and therapeutics for HIV and AIDS)

RN 307301-89-9 CAPLUS

CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-thienyl]-N-[trans-4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]cyclohexyl]-, (2E)- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT **307301-90-2P 307301-94-6P 307301-96-8P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of cyclic compds. having antagonism against CCR 5 receptor for preventives and therapeutics for HIV and AIDS)

RN 307301-90-2 CAPLUS

CN 2-Propenamide, 3-[4-(4-methylphenyl)-2-thienyl]-N-[trans-4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]cyclohexyl]-, (2E)- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 307301-94-6 CAPLUS
CN 2-Propenamide, 3-[4-(4-methylphenyl)-2-furanyl]-N-[trans-4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]cyclohexyl]-, (2E)- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 307301-96-8 CAPLUS
CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[trans-4-[[(2E)-3-[4-(4-methylphenyl)-2-furanyl]-1-oxo-2-propenyl]amino]cyclohexyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



● I^-

IT **229007-97-0 229008-01-9 307301-92-4**
RL: RCT (Reactant)
(prepn. of cyclic compds. having antagonism against CCR 5 receptor for preventives and therapeutics for HIV and AIDS)

RN 229007-97-0 CAPLUS
CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-01-9 CAPLUS
CN 2-Propenoic acid, 3-[4-(4-methylphenyl)-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 307301-92-4 CAPLUS
CN 2-Propenoic acid, 3-[4-(4-methylphenyl)-2-furanyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 14
RE
(1) American Chemical Society; CAPLUS
(3) Takeda Chemical Industries Ltd; JP 11263764 A CAPLUS
(4) Takeda Chemical Industries Ltd; JP 2000128782 A CAPLUS
(5) Takeda Chemical Industries Ltd; JP 2000128842 A CAPLUS
(6) Takeda Chemical Industries Ltd; US 6096780 A CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 2000:191072 CAPLUS
DN 132:238690
TI Synthesis of 5,5'-diformyl-2-2'-difuran and its derivatives and apparatus therefor
IN Burger, Gregory James; Wills, Alan Douglas
PA S. Afr.
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000015623	A1	20000323	WO 1999-ZA87	19990915
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9964346	A1	20000403	AU 1999-64346	19990915
EP 1036071	A1	20000920	EP 1999-952044	19990915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI ZA 1998-8414 19980915
WO 1999-ZA87 19990915

AB 5,5'-Diformyl-2,2'-difuran and derivs. thereof are synthesized by irradiating furfural or a deriv. thereof by itself or with a substance capable of reacting or condensing therewith. The prodn. of these potential monomers is achieved in good yield and purity and avoids the use of high temps., metal powders, and tedious work-up procedures of prior-art methods. Typically, 5,5'-diformyl-2,2'-difuran was prepd. in good yield by photochem. irradiating furfural or a mixt. of furfural and 5-bromo-2-furfural. In the latter case an acid scavenger is present. The process may be carried out continuously, the 5-bromo-2-furfural acting as a catalyst, the furfural being added, and the product being harvested continuously.

IT **261712-43-0P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(photochem. synthesis of 5,5'-diformyl-2-2'-difuran and derivs. thereof)

RN 261712-43-0 CAPLUS
CN 2-Propen-1-one, 3,3'-[2,2'-bifuran]-5,5'-diylbis[1-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 3
RE
(1) Itahara, T; JOURNAL OF ORGANIC CHEMISTRY 1985, V50(25), P5272 CAPLUS
(2) Maerkl, G; TETRAHEDRON 1996, V52(36), P11763 CAPLUS
(3) Tymyanskii, Y; JOURNAL OF ORGANIC CHEMISTRY OF THE USSR, ENGLISH TRANSLATION 1988, V24(2), P407

L28 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1999:747238 CAPLUS
DN 132:7605
TI Laser information recording medium and novel oxonol compound
IN Saito, Naoki; Wariishi, Koji; Shibata, Michihiro
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 43 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 11321110	A2	19991124	JP 1998-153877	19980519

OS MARPAT 132:7605
GI For diagram(s), see printed CA Issue.
AB The title recording medium contains an oxonol compd. I (R1, R2, R3= substituent; Xk+ = onium ion; r = 1-5; n = 0, 1; p, q = 0-4 (p+q .gtoreq. 1); when p or q is .gtoreq.2, 2 R1 or R2 may joint with benzene ring to form condensed ring; k = 1-10) in its recording layer, wherein the center of the methine group may be substituted with Me, Et, Ph, 4-pyridyl, methoxy, phenoxy. The invention recording material shows superior reading property and stability of the recording property for a long time.
IT **250787-58-7**
RL: TEM (Technical or engineered material use); USES (Uses)
(contained in recording layer for optical recording material)
RN 250787-58-7 CAPLUS
CN 4,4'-Bipyridinium, 1,1'-bis(2-methyl-1-propenyl)-, salt with 2-[5-(3-hydroxy-1,1-dioxidobenzo[b]thien-2-yl)-3-phenyl-2,4-pentadienylidene]benzo[b]thiophen-3(2H)-one 1,1-dioxide (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 250787-57-6
CMF C18 H22 N2



CM 2

CRN 250787-50-9
CMF C27 H17 O6 S2



L28 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1999:421672 CAPLUS
DN 131:73571
TI Preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compounds as MCP-1 receptor antagonists.
IN Shiraishi, Mitsuru; Kitayoshi, Takahito; Aramaki, Yoshio; Honda, Susumu; Oda, Tsuneo
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 513 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932468	A1	19990701	WO 1998-JP5707	19981217
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 9813686	A	20001010	BR 1998-13686	19981212
	AU 9916830	A1	19990712	AU 1999-16830	19981217
	EP 1040103	A1	20001004	EP 1998-961383	19981217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6166006	A	20001226	US 1998-213379	19981217
	JP 11263764	A2	19990928	JP 1998-360780	19981218
	NO 2000003133	A	20000809	NO 2000-3133	20000616

PRAI JP 1997-351481 19971219
WO 1998-JP5707 19981217
OS MARPAT 131:73571
GI



I





AB Title compds. I [R1 = (substituted) 5-6 membered ring; W = Q1, Q2; A = atoms to form a (substituted) 5-6 membered arom. ring; X = S, O,

(substituted) C, N; B = atoms to form a (substituted) 5-7 membered ring; Z = bond, divalent group; R2 = (substituted) amino, ammonio, heterocyclyl, S-bonded group, P(O)kR5R6; k = 0, 1; R5, R6 = (substituted) hydrocarbyl, amino; PR5R6 = cyclic group], were prepd. Thus, 7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxylic acid in CH2Cl2 was treated with (COCl)2 and DMF to give a residue which was stirred with 4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]aniline and Et3N in THF to give N-[4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]phenyl]-7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide (II). II at 1 .mu.M inhibited MCP-1 induced chemotaxis in CHO cells by 89%. A II capsule compn. is given.

IT **229005-41-8P 229005-42-9P 229005-43-0P**
229005-44-1P 229005-45-2P 229005-46-3P
229006-01-3P 229006-02-4P 229006-06-8P
229006-08-0P 229006-11-5P 229006-12-6P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229005-41-8 CAPLUS
CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229005-42-9 CAPLUS
CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229005-43-0 CAPLUS
CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-furanyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229005-44-1 CAPLUS
CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-furanyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229005-45-2 CAPLUS
CN 2-Propenamide, 3-[4-(4-methylphenyl)-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229005-46-3 CAPLUS
CN 2-Propenamide, 3-[4-(4-methylphenyl)-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229006-01-3 CAPLUS
CN 2-Propenamide,
3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229006-02-4 CAPLUS
CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229006-06-8 CAPLUS
CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229006-08-0 CAPLUS
CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229006-11-5 CAPLUS
CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[(2E)-3-[5-(4-methylphenyl)-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229006-12-6 CAPLUS
CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[(2E)-3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **62806-32-0P 229007-96-9P 229007-97-0P**
229007-99-2P 229008-00-8P 229008-01-9P
229008-54-2P 229008-55-3P 229008-56-4P
229008-57-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 62806-32-0 CAPLUS
CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-furanyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229007-96-9 CAPLUS
CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229007-97-0 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229007-99-2 CAPLUS
CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-furanyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-00-8 CAPLUS
CN 2-Propenoic acid, 3-[4-(4-methylphenyl)-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-01-9 CAPLUS
CN 2-Propenoic acid, 3-[4-(4-methylphenyl)-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-54-2 CAPLUS
CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-55-3 CAPLUS
CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-56-4 CAPLUS
CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-57-5 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, (2E)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 2
RE
(1) Teijin Ltd; JP 07025756 A 1995 CAPLUS
(2) Teijin Ltd; JP 07025757 A 1995 CAPLUS

L28 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1999:421562 CAPLUS
DN 131:87834
TI Preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compounds as CCR5 antagonists.
IN Nishimura, Osamu; Baba, Masanori; Sawada, Hidekazu; Kanzaki, Naoyuki; Kuroshima, Ken-ichi; Shiraishi, Mitsuru; Aramaki, Yoshio
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 516 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932100	A2	19990701	WO 1998-JP5708	19981217
	WO 9932100	A3	19990910		
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9916831	A1	19990712	AU 1999-16831	19981217
	EP 1039899	A2	20001004	EP 1998-961384	19981217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9813691	A	20001010	BR 1998-13691	19981217
	JP 2000128782	A2	20000509	JP 1998-360820	19981218
	US 6096780	A	20000801	US 1999-377040	19990819
	NO 2000003179	A	20000619	NO 2000-3179	20000619
PRAI	JP 1997-351480	19971219			
	JP 1998-218875	19980803			
	JP 1998-234388	19980820			
	JP 1998-234398	19980820			
	US 1998-104845	19981016			
	WO 1998-JP5708	19981217			

OS MARPAT 131:87834
GI



I





AB A pharmaceutical compn. for antagonizing CCR5 comprises I [R1 = (substituted) 5-6 membered ring; W = Q1, Q2; A = atoms to form a (substituted) 5-6 membered arom. ring; X = S, O, (substituted) C, N; B = atoms to form a (substituted) 5-7 membered ring; Z = bond, divalent group;
R2 = (substituted) amino, ammonio, heterocyclyl, S-bonded group, P(O)kR5R6; k = 0, 1; R5, R6 = (substituted) hydrocarbyl, amino; PR5R6 = cyclic group]. Thus, 7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxylic acid in CH2Cl2 was treated with (COCl)2 and DMF to give a residue which was stirred with 4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]aniline and Et3N in THF to give N-[4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]phenyl]-7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide (II). A II capsule compn. is given.

IT **229005-41-8P 229005-42-9P 229005-43-0P**
229005-44-1P 229005-45-2P 229005-46-3P
229006-01-3P 229006-02-4P 229006-06-8P
229006-08-0P 229006-11-5P 229006-12-6P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229005-41-8 CAPLUS

CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229005-42-9 CAPLUS
CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229005-43-0 CAPLUS
CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-furanyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229005-44-1 CAPLUS
CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-furanyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229005-45-2 CAPLUS
CN 2-Propenamide, 3-[4-(4-methylphenyl)-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229005-46-3 CAPLUS
CN 2-Propenamide, 3-[4-(4-methylphenyl)-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229006-01-3 CAPLUS
CN 2-Propenamide,
3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229006-02-4 CAPLUS
CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229006-06-8 CAPLUS
CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229006-08-0 CAPLUS
CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229006-11-5 CAPLUS
CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[(2E)-3-[5-(4-methylphenyl)-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● I^-

RN 229006-12-6 CAPLUS
CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[(2E)-3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● I^-

IT **62806-32-0P 229007-96-9P 229007-97-0P 229007-99-2P 229008-00-8P 229008-01-9P 229008-54-2P 229008-55-3P 229008-56-4P 229008-57-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)
RN 62806-32-0 CAPLUS
CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-furanyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229007-96-9 CAPLUS
CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229007-97-0 CAPLUS
CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229007-99-2 CAPLUS
CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-furanyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-00-8 CAPLUS
CN 2-Propenoic acid, 3-[4-(4-methylphenyl)-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-01-9 CAPLUS
CN 2-Propenoic acid, 3-[4-(4-methylphenyl)-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-54-2 CAPLUS
CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-55-3 CAPLUS
CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-56-4 CAPLUS
CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-57-5 CAPLUS
CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L28 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1998:661889 CAPLUS
DN 129:343825
TI Organic thin films and their production method by photochemical reaction
IN Nakao, Yukiyasu; Fuchigami, Hiroyuki; Kurata, Hiroyuki; Kakuta, Makoto
PA Mitsubishi Electric Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10273529	A2	19981013	JP 1997-78290	19970328

AB The films of oligomers and/or polymers deposited on substrates are obtained by photochem. reaction of same or different kinds of low-mol.-wt. arom. compds. The reaction processes involves heating the arom. compds. in vacuo to generate their mol. beams, then exposing the beams on substrates, simultaneously irradiating visible light or UV light to the mols. provided that .gtoreq.1 of the mols. can absorb the light. Thus, evapg. biphenyl dithiol and biphenyl diethynyl in vacuo and irradiating laser at wave length 248 nm to the mols. gave a transparent deposition film having smooth surface.

IT **215360-51-3P**, 4,4'-Diacetylbiphenyl-diethynylbithiophene copolymer,sru
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(vapor deposition of arom. org. films by photopolymn.)

RN 215360-51-3 CAPLUS
CN Poly[[2,2'-bithiophene]-5,5'-diyl(3-oxo-1-propene-1,3-diyl)[1,1'-biphenyl]-4,4'-diyl(1-oxo-2-propene-1,3-diyl)] (9CI) (CA INDEX NAME)

PAGE 1-A




n

L28 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1998:424230 CAPLUS
DN 129:81730
TI Preparation of (hetero)arylacrylates as modulators of proteins with phosphotyrosine recognition units.
IN Mjalli, Adnan; Sarshar, Sepehr; Cao, Xiaodong; Bakir, Farid
PA Ontogen Corp., USA
SO PCT Int. Appl., 202 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9827065	A1	19980625	WO 1996-US20508	19961216
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9715667	A1	19980715	AU 1997-15667	19961216
EP 946518	A1	19991006	EP 1996-945409	19961216
R: CH, DE, ES, FR, GB, IT, LI, SE				
PRAI US 1995-543630		19951016		
WO 1996-US20508		19961216		

OS MARPAT 129:81730
GI



I

AB YXC(R'):C(R")CO2R''' [R', R'' = H, halo, cyano, NO2, trihalomethyl, alkyl, arylalkyl; R''' = H, (substituted) alkyl, aryl, arylalkyl; X = aryl; Y = H, (substituted) CO2CHCO, COCO, COCHOH, imidazolyl, thiazolyl, oxazolyl, quinoxalinyl, pyridopyrazinyl, etc.], were prepd. Thus, title compd. (I) (general prepn. given) inhibited protein tyrosine phosphatase 1B with IC50

= 0.072 .mu.M.

IT **207867-36-5P 207867-37-6P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (hetero)arylacrylates as modulators of proteins with phosphotyrosine recognition units)

RN 207867-36-5 CAPLUS
CN Hexanoic acid,
6-[[[2-[5-(2-carboxyethenyl)-2-thienyl]-4-(4-methoxyphenyl)-1-(2-phenylpropyl)-1H-imidazol-5-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 207867-37-6 CAPLUS
CN Hexanoic acid,
6-[[[2-[5-(2-carboxyethenyl)-2-thienyl]-4-(4-methoxyphenyl)-1-(2-phenylpropyl)-1H-imidazol-5-yl]carbonyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 207867-36-5
CMF C33 H35 N3 O6 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L28 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1998:352632 CAPLUS
DN 129:27942
TI Imidazole derivatives useful as modulators of multi drug resistances
IN Mjalli, Adnan M. M.; Sarshar, Sepehr
PA Ontogen Corp., USA
SO U.S., 24 pp. Cont.-in-part of U.S. 5,700,826.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5756527	A	19980526	US 1997-845322	19970425
	US 5700826	A	19971223	US 1995-481118	19950607
	AU 9724827	A1	19981029	AU 1997-24827	19970611
	JP 11001476	A2	19990106	JP 1997-192989	19970613
PRAI	US 1995-481118	19950607			
	US 1997-845322	19970425			

OS MARPAT 129:27942
GI



I



II

AB The title compds. [I; R1 = mono-, di-, and tri-substituted Ph or thienyl, etc.; R2, R3 = mono-, di, and tri-substituted Ph wherein the substituents are independently selected from: (i) halo; (ii) C1-6 alkylamino, or di(C1-6 alkyl)amino; R4 = H] are prepd. I are useful for restoring the sensitivity of multidrug resistant cells to cancer chemotherapeutic agents. Thus, a mixt. of the proper dione, aldehyde and AcONH4 in AcOH was heated to 80-140.degree. to give 82% the title compd. (II), which was tested and showed 3H-vinblastine accumulation of 2.4 (.mu.M)2 in the CEM/VLB1000 cell line.

IT **208036-56-0P 208036-57-1P 208036-60-6P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(imidazole derivs. useful as modulators of multi drug resistances)

RN 208036-56-0 CAPLUS
CN 2-Propenoic acid,
3-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-yl]-
2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 208036-57-1 CAPLUS
CN 2-Propenoic acid,
3-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-yl]-
3-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 208036-60-6 CAPLUS
CN 2-Propenoic acid,
3-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-yl]-
2-thienyl]-, 1-methylethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


NMe2
H
N
i-PrO
E
S
N
O
NMe2

L28 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1998:324830 CAPLUS
DN 129:27883
TI Preparation of thiophene derivatives as immunostimulants
IN Chang, Ching-te; Chen, Kuo-mou; Liu, Wann-huang; Lin, Fen-lan; Wu, Rong-tsun
PA Industrial Technology Research Institute, Taiwan
SO U.S., 29 pp. Cont.-in-part of U.S. Ser. No. 302,278.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5753692	A	19980519	US 1995-468522	19950606
	US 5602170	A	19970211	US 1994-302278	19940908
PRAI	US 1992-838516		19920219		
	US 1994-302278		19940908		

OS MARPAT 129:27883
AB AZmB [I; A,B = H, halo, alk(en)yl, carboxy(alkyl), etc.; Z = 2,5-thiophenediyl; m = 1-4] were prepd. Thus, 2-iodothiophene was autocondensed to give 2,2'-bithiophene. Data for biol. activity of I were given.
IT **162691-96-5P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thiophene derivs. as immunostimulants)
RN 162691-96-5 CAPLUS
CN 2-Propen-1-one, 3-[2,2'-bithiophen]-5-yl-1-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 10-35

L28 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1998:324829 CAPLUS
DN 129:27943
TI Preparation of heterocyclic compounds as modulators of proteins with phosphotyrosine recognition units
IN Mjalli, Adnan; Sarshar, Sepehr; Cao, Xiaodong; Bakir, Farid
PA Ontogen Corp., USA
SO U.S., 50 pp. Cont.-in-part of U.S. Ser. No. 543,630.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5753687	A	19980519	US 1996-766114	19961216
	US 5770620	A	19980623	US 1995-543630	19951016
	US 5965558	A	19991012	US 1997-960637	19971029
	US 6150532	A	20001121	US 1998-210076	19981211

PRAI US 1995-543630 19951016
US 1995-17610 19950619
US 1996-766114 19961216
US 1997-960637 19971029
OS MARPAT 129:27943
GI



I

AB The title compds. I [at least one of R1 - R4 is XC(R'):C(R'')CO2R'''; R', R'' = H, halo, etc.; R''' = H, alkyl, etc.; X = mono-, di-, or trisubstituted aryl; the remaining of R1, R2, R3, R4 are independently selected from H, alkyl, etc.] are prepd. The title compds. in vitro showed IC50 values of 0.072 .mu.M to 31 .mu.M against PTP1B.
IT **207867-37-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of heterocyclic compds. as modulators of proteins with phosphotyrosine recognition units)
RN 207867-37-6 CAPLUS
CN Hexanoic acid,
6-[[[2-[5-(2-carboxyethenyl)-2-thienyl]-4-(4-methoxyphenyl)-1-(2-phenylpropyl)-1H-imidazol-5-yl]carbonyl]amino]-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 207867-36-5

CMF C33 H35 N3 O6 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L28 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1998:282404 CAPLUS
DN 128:321558
TI Preparation of thiophene compounds as antiinflammatory and antitumor agents
IN Chang, Ching-te; Chen, Kuo-mou; Liu, Wann-huang; Lin, Fen-lan; Wu, Rong-tsun
PA Industrial Technology Research Institute, Taiwan
SO U.S., 34 pp. Cont.-in-part of U.S. 5,602,170.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5747525	A	19980505	US 1995-468253	19950606
	US 5602170	A	19970211	US 1994-302278	19940908
PRAI	US 1992-838516		19920219		
	US 1994-302278		19940908		

OS MARPAT 128:321558
AB AZmB [I; A,B = H, halo, alkyl, carboxy(alkyl), alkoxy, etc.; Z = 2,5-thiophenediyl; m = 1-4] were prepd. Thus, 2-iodothiophene was subjected to Ullman reaction and the product subjected to Vilsmier reaction to give HZ2CHO. Data for biol. activity of I were given.
IT **162691-96-5P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thiophene compds. as antiinflammatory and antitumor agents)
RN 162691-96-5 CAPLUS
CN 2-Propen-1-one, 3-[2,2'-bithiophen]-5-yl-1-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



L28 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1998:81044 CAPLUS
DN 128:192655
TI Preparation of 4-phenylpyridine derivatives as endothelin antagonists
IN Sakurai, Kuniya; Niwa, Seiji; Oono, Seiji; Uchita, Hirohisa
PA Ajinomoto Co., Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 95 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10029979	A2	19980203	JP 1997-93782	19970411
PRAI	JP 1996-91272	19960412			

OS MARPAT 128:192655
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. (I; R1 - R11 = H, halo, OH, NH2, NO2, lower alkyl, alkoxy, alkenyl, alkylamino, alkylthio, alkanoyl, hydroxyalkyl, hydroxyalkoxy, hydroxyalkenyl, haloalkyl, haloalkoxy, or haloalkenyl, aryl-lower alkoxy, aroyl; or two of R1 - R5 groups or two of R7 - R11 groups are linked to each other to form a ring; R6 = an acidic functional group; R12 = aryl, heteroaryl, heterocyclylcarbonyl, or groups listed for R1 - R5 and R7 - R11; X = CR13R14, NR15, O, S; Y = NR16, O, S, CR17:CR18; R13 - R18 = H, lower alkyl; Z = H, OH, CO2H, lower alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkylcarbamoyl, arylcarbamoyl, heteroarylcarbamoyl, NH2, alkylamino, arylamino, heteroarylamino, acylamino, O2CNR19R20, NR21CONR22R23, O-CO2R24, NR25CO2R26, OR27, O2CR28; R19 - R28 = H, lower alkyl, aryl, heteroaryl; or R19 and R20, R21 and R22, R21 and R23, R22 and R23, or R25 and R26 are bonded to each other to form a ring; m = 0,1; n = 0-3) are prepd. They are useful for the treatment of hypertension, Raynaud's disease, acute kidney failure, myocardial infarction, angina pectoris, cerebral infarction, atrophy of brain blood vessels, arteriosclerosis, bronchial asthma, stomach ulcer, acute liver failure, diabetes, endotoxin shock, multi-organ failure, disseminated intravascular agglutination, and/or cyclosporin-induced kidney disorders. Thus, 3-cyano-5-(3-hydroxy-1-propenyl)-4-(4-methoxyphenyl)-6-methyl-2-(3,4-methylenedioxyphenyl)pyridine was dissolved in toluene, treated with Bu3SnN3, and refluxed overnight to give 60.5% the title 4-phenyl-3-tetrazolylpyridine compd. (II). II in vitro inhibited the binding of [125I]endotoxin to a pig ventricular muscle membrane prepn. with a -pIC50 value of 8.1.

IT **203801-69-8P 203801-70-1P 203802-12-4P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)
(prepn. of phenylpyridine derivs. as endothelin antagonists for treatment endothelin-related diseases)

RN 203801-69-8 CAPLUS
CN Carbamic acid, 2-furanyl-, 3-[6-(1,3-benzodioxol-5-yloxy)-4-(4-methoxyphenyl)-2-methyl-5-(1H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl ester
(9CI) (CA INDEX NAME)



RN 203801-70-1 CAPLUS
CN 2-Furancarboxylic acid, 3-[6-(1,3-benzodioxol-5-yloxy)-4-(4-methoxyphenyl)-2-methyl-5-(1H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl ester (9CI) (CA INDEX NAME)



RN 203802-12-4 CAPLUS
CN 2-Propen-1-ol, 3-[6-(1,3-benzodioxol-5-yloxy)-2-(2-furanyl)-4-(4-methoxyphenyl)-5-(1H-tetrazol-5-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



IT **203804-83-5P 203804-84-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of phenylpyridine derivs. as endothelin antagonists for treatment endothelin-related diseases)
RN 203804-83-5 CAPLUS
CN 2-Propenoic acid, 3-[6-(1,3-benzodioxol-5-yloxy)-5-cyano-2-(2-furanyl)-4-(4-methoxyphenyl)-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203804-84-6 CAPLUS
CN 3-Pyridinecarbonitrile, 2-(1,3-benzodioxol-5-yloxy)-6-(2-furanyl)-5-(3-hydroxy-1-propenyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L28 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1997:684407 CAPLUS
DN 127:346232
TI Cephem derivatives containing substituted heterocyclylpyridiniomethyl group antibacterials
IN Nishitani, Yasuhiro; Ishikura, Koji
PA Shionogi & Co. Ltd., Japan; Nishitani, Yasuhiro; Ishikura, Koji
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT **Patent**
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9737996	A1	19971016	WO 1997-JP1161	19970404
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2250002	AA	19971016	CA 1997-2250002	19970404
	AU 9721784	A1	19971029	AU 1997-21784	19970404
	EP 893446	A1	19990127	EP 1997-914600	19970404
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, FI				
	CN 1215403	A	19990428	CN 1997-193623	19970404
PRAI	JP 1996-82531	19960404			
	WO 1997-JP1161	19970404			

OS MARPAT 127:346232
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Cephem compds. such as I having groups of general formula II [Het = a mono- or poly-cyclic hetero-ring having one or more atoms selected from among N, O and S which may be the same or different from each other; R1 = H, optionally substituted lower alkyl or lower alkenyl; A = optionally substituted lower alkylene, lower alkenylene or a single bond while B = optionally substituted imino or a single bond, or alternatively A and B may be united to form a single bond; and D = a single bond or NH-CMe:NH] at the 3-position of the cephem ring, or salts or hydrates thereof, are prepd. Thus, III [R2 = CHO, R3 = H] in DMF was treated with (BOC)2O to give III [R2 = CHO, R3 = BOC], which was treated with MeO-NH2.H2O in MeOH to give III [R2 = CH:N-OMe, R3 = BOC], which was reduced with Zn and the resulting (aminomethyl)pyrrole deriv. treated with 1,1'-carbonyldiimidazole in THF to give III [R2 = 1-imidazolylcarbonylaminomethyl, R3 = BOC], which was reacted with cyanamide
in DMF contg. NaH to give III [R2 = CH2-NH-CO-NH-CN, R3 = BOC]. This was

reacted with cephem deriv. IV (PMB = p-methoxybenzyl) in MeCN-DMSO and the product treated with AlCl3 and anisole in CH2Cl2 followed by HCl in EtOH to give the title compd. V. In an in vitro study this had an MIC of 0.006 .mu.g/mL against Streptococcus pyogenes.

IT **197776-37-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(cephem derivs. contg. substituted heterocyclylpyridiniomethyl group as antibacterials)

RN 197776-37-7 CAPLUS

CN Pyridinium, 4-[5-[3-(cyanoamino)-3-oxo-1-propenyl]-3-thienyl]-1-[[7-[[[5-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,4-thiadiazol-3-yl](ethoxyimino)acetyl]amino]-2-[[(4-methoxyphenyl)methoxy]carbonyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt, [6R-[3(E),6.alpha.,7.beta.(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L28 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1997:623162 CAPLUS
DN 127:293119
TI Preparation of bicyclic aromatic compounds
IN Bernardon, Jean-Michel
PA Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galder, Fr.; Bernardon, Jean-Michel
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT **Patent**
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9733881	A1	19970918	WO 1997-FR391	19970305
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	FR 2746101	A1	19970919	FR 1996-3235	19960314
	FR 2746101	B1	19980430		
	CA 2218766	AA	19970918	CA 1997-2218766	19970305
	AU 9720305	A1	19971001	AU 1997-20305	19970305
	AU 704753	B2	19990506		
	EP 832081	A1	19980401	EP 1997-908308	19970305
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1190394	A	19980812	CN 1997-190489	19970305
	JP 10509987	T2	19980929	JP 1997-532318	19970305
	JP 2991502	B2	19991220		
	BR 9702200	A	19990720	BR 1997-2200	19970305
	NO 9705192	A	19980114	NO 1997-5192	19971112
	US 6147255	A	20001114	US 1998-952804	19980126
PRAI	FR 1996-3235	19960314			
	WO 1997-FR391	19970305			

OS MARPAT 127:293119
GI



I

AB Novel bicyclic arom. compds. I [R1 = Me, CH2OR5, COR6; Ar = = (un)substituted Ph, pyridyl, furyl, thienyl, pyrrolyl; X = CR8:CR9, C.tplbond.C; R2, R3 = H, alkyl, OR5, SR5; R2R3 = arom. ring; R5 = H,

alkyl, acyl; R6 = H, alkyl, NR'R''; R8, R9 = H, alkyl] and their use in pharmaceutical compns. useful in treatment of dermatol. conditions (no data) or their use in cosmetic compns. (no data) are disclosed. E.g., reaction of 3-tert-butyl-4-methoxyphenylboronic acid and 4-bromo-2-thiophenecarboxaldehyde gave 4-(3-tert-butyl-4-methoxyphenyl)-2-thiophenecarboxaldehyde. The last was treated with tri-Et phosphonoacetate to give Et 4-(3-tert-butyl-4-methoxyphenyl)-2-thiopheneacrylate. The ester was converted to the corresponding acid.

IT **196960-59-5P 196960-61-9P 196960-62-0P 196960-63-1P 196960-64-2P 196960-65-3P**
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bicyclic arom. compds.)

RN 196960-59-5 CAPLUS
CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 196960-61-9 CAPLUS
CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 196960-62-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 196960-63-1 CAPLUS
CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 196960-64-2 CAPLUS
CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 196960-65-3 CAPLUS
CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)



IT **196961-00-9P 196961-02-1P 196961-04-3P**
196961-06-5P 196961-08-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of bicyclic arom. compds.)

RN 196961-00-9 CAPLUS
CN 2-Propenoic acid,
3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-
, ethyl ester (9CI) (CA INDEX NAME)



RN 196961-02-1 CAPLUS
CN 2-Propenoic acid,
3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-
, ethyl ester (9CI) (CA INDEX NAME)



RN 196961-04-3 CAPLUS
CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-
naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 196961-06-5 CAPLUS

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 196961-08-7 CAPLUS

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



L28 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1997:128100 CAPLUS
DN 126:225209
TI Preparation of thiophene derivatives as drugs
IN Chang, Ching-te; Chen, Kuo-mou; Liu, Wann-huang; Lin, Fen-lan; Wu, Rong-tsun
PA Industrial Technology Research Institute, Taiwan
SO U.S., 30 pp. Cont.-in-part of U.S. Ser. No. 838,516, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5602170	A	19970211	US 1994-302278	19940908
	US 5747525	A	19980505	US 1995-468253	19950606
	US 5753692	A	19980519	US 1995-468522	19950606
PRAI	US 1992-838516	19920219			
	US 1994-302278	19940908			

OS MARPAT 126:225209
AB AZmB [I; A,B = H, alkyl, alken(o)yl, alkynyl, alkoxy, etc.; Z = thiophene-2,5-diyl; m = 1-4] were prepd. as antiinflammatory, antitumor, and antiviral agents, immunomodulators, etc. Thus, 2-iodothiophene was coupled over Cu and the formylated product converted in 2 steps to 5-ethynyl-2,2'-bithiophene. Data for biol. activity of I were given.
IT **162691-96-5P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thiophene derivs. as drugs)
RN 162691-96-5 CAPLUS
CN 2-Propen-1-one, 3-[2,2'-bithiophen]-5-yl-1-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



L28 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1997:127476 CAPLUS
DN 126:126920
TI Inhibition of phospholipase A2 for treatment of neurodegenerative disease,
method for identification of inhibitors of neuronal degeneration, and benzenesulfonamide phospholipase A2 inhibitor preparation
IN Rydel, Russel E.; Dappen, Michael S.; John, Varghese; Fang, Lawrence Yung-Sun; Thorsett, Eugene D.
PA Athena Neurosciences, Inc., USA; Rydel, Russel E.; Dappen, Michael S.; John, Varghese; Fang, Lawrence Yung-Sun; Thorsett, Eugene D.
SO PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640982	A1	19961219	WO 1996-US9772	19960607
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
	US 5707821	A	19980113	US 1995-476464	19950607
	US 5866318	A	19990202	US 1995-476463	19950607
	AU 9663814	A1	19961230	AU 1996-63814	19960607
PRAI	US 1995-476463	19950607			
	US 1995-476464	19950607			
	US 1995-486392	19950607			
	WO 1996-US9772	19960607			

GI



I

AB Methods and compns. are provided for treating neurodegeneration in mammalian cells by administering a phospholipase A2 inhibitor. Also disclosed are methods for identifying agents which inhibit neuronal degeneration. Prepn. and activity of benzenesulfonamide phospholipase A2 inhibitors, e.g. AN36653 (I), is included.
IT **186457-39-6P**, AN 36724
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(phospholipase A2 inhibition for treatment of neurodegenerative disease, method for identification of inhibitors of neuronal degeneration, and benzenesulfonamide phospholipase A2 inhibitor prepn.)
RN 186457-39-6 CAPLUS
CN 2-Propenamide,
3-[2,2'-bithiophen]-5-yl-N-[4-[(cycloheptylamino)sulfonyl]phenyl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L28 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1997:85609 CAPLUS
DN 126:199793
TI Preparation of pyrazoloquinoline nucleosides as antitumors
IN Wolin, Ronald L.; Afonso, Adriano; Kelly, Joseph M.; Njoroge, F. George
PA Wolin; Ronald L., USA; Afonso; Adriano; Kelly; Joseph M.; Njoroge; F. George
SO U.S., 24 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5595998	A	19970121	US 1994-357624	19941215

OS MARPAT 126:199793
GI



AB Pyrazoloquinoline nucleosides I and II (R1 = CH2OH, alkyloxymethyl, CH2NH2, BnCO2CH2, BnOCH2, BzCH:CH; R2,R3 = OH, alkyl, COO, BnCOO, BnO; X = Cl, OH, H) as antitumors. Thus, I (R1-R3 = OBz; X = Cl) was prepd. and tested for its antitumor activity (ras p21 nucleotide exchange assay 17%; IC50 = 50 .mu.M).

IT **175543-50-7P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of pyrazoloquinoline nucleosides as antitumors)

RN 175543-50-7 CAPLUS
CN 2-Propen-1-one, 3-[5-(4-chloro-6-methoxy-3-methyl-1H-pyrazolo[3,4-b]quinolin-1-yl)-2-furanyl]-1-phenyl- (9CI) (CA INDEX NAME)


O
CH═CH–C–Ph
O
N
N
N
Me
OMe
Cl

L28 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1996:580361 CAPLUS
DN 125:221564
TI Preparation of diphenylthiophene antiinflammatories
IN Wierzbicki, Michel; Sauveur, Frederic; Bonnet, Jacqueline; Tordjman, Charles
PA Adir Et Compagnie, Fr.
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT **Patent**
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 728755	A1	19960828	EP 1996-400359	19960222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	FR 2730996	A1	19960830	FR 1995-2061	19950223
	FR 2730996	B1	19970620		
	CN 1142496	A	19970212	CN 1996-106004	19960217
	CN 1058965	B	20001129		
	FI 9600795	A	19960824	FI 1996-795	19960221
	AU 9645675	A1	19960829	AU 1996-45675	19960221
	AU 697832	B2	19981015		
	CA 2170097	AA	19960824	CA 1996-2170097	19960222
	NO 9600706	A	19960826	NO 1996-706	19960222
	JP 08253470	A2	19961001	JP 1996-35131	19960222
	US 5705525	A	19980106	US 1996-605537	19960222
	ZA 9601472	A	19960828	ZA 1996-1472	19960223
PRAI	FR 1995-2061		19950223		

OS MARPAT 125:221564
GI



I



II

AB The title compds. [I; A = (un)substituted C1-5 alkylene; R1 = branched alkyl, H; R2 = H, alkyl, cyclohexyl, PhCH2; X1, X2, Y1, Y2 = H, halogen, alkoxy, alkyl, CF3], useful as antiinflammatories, are prepd. Thus, thiophene deriv. II, m.p. 96.degree., prepd. from the corresponding Et ester, demonstrated a IC50 for cyclooxygenase (PGE2) of 0.05 .mu.M and 0.03 .mu.M for lipoxygenase (LTB4).

IT **181309-29-5P 181309-30-8P 181309-31-9P**
181309-32-0P 181309-33-1P 181309-34-2P
181309-35-3P 181309-36-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of diphenylthiophene antiinflammatories)

RN 181309-29-5 CAPLUS

CN 2-Propenoic acid, 3-[4,5-bis(4-methoxyphenyl)-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 181309-30-8 CAPLUS
CN 2-Propenoic acid, 3-[4-(4-fluorophenyl)-5-(4-methoxyphenyl)-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 181309-31-9 CAPLUS
CN 2-Propenoic acid, 3-[5-(4-methoxyphenyl)-4-(4-methylphenyl)-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 181309-32-0 CAPLUS
CN 2-Propenoic acid, 3-[5-(4-methoxyphenyl)-4-[4-(trifluoromethyl)phenyl]-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 181309-33-1 CAPLUS
CN 2-Propenoic acid, 3-[4-(4-chlorophenyl)-5-(4-methoxyphenyl)-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 181309-34-2 CAPLUS
CN 2-Butenoic acid, 3-[4,5-bis(4-methoxyphenyl)-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 181309-35-3 CAPLUS
CN 2-Propenoic acid, 3-[5-(4-chlorophenyl)-4-(4-methoxyphenyl)-2-thienyl]-,

ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 181309-36-4 CAPLUS
CN 2-Propenoic acid, 3-[4,5-bis(4-methylphenyl)-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L28 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1996:497113 CAPLUS
DN 125:142773
TI Novel benzyl pyrimidines with antibacterial activity.
IN Guerry, Philippe; Jolidon, Synese; Masciadri, Raffaello; Stalder, Henri; Then, Rudolf
PA F. Hoffmann-La Roche Ag, Switz.
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9616046	A2	19960530	WO 1995-EP4451	19951113
	W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9641161	A1	19960617	AU 1996-41161	19951113
	AU 704911	B2	19990506		
	EP 793656	A1	19970910	EP 1995-939267	19951113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1166831	A	19971203	CN 1995-196398	19951113
	HU 77372	A2	19980330	HU 1997-1973	19951113
	BR 9509768	A	19980707	BR 1995-9768	19951113
	JP 11507009	T2	19990622	JP 1995-516521	19951113
	US 5763450	A	19980609	US 1997-836857	19970521
	FI 9702194	A	19970522	FI 1997-2194	19970522
	NO 9702393	A	19970529	NO 1997-2393	19970526

PRAI CH 1994-3536 19941124
CH 1995-2704 19950925
WO 1995-EP4451 19951113
OS MARPAT 125:142773
GI



I

II



III

AB Substituted 5-benzyl-2,4-diaminopyrimidines of formula I [R1 = alkoxy; R2 = Br or alkoxy; R3 = aryl, heteroaryl, QR4; Q = CH2CH2, CH:CH, C.tplbond.C; R4 = aryl, heteroaryl, alkoxycarbonyl, or carbamoyl], and their readily hydrolyzable esters and pharmaceutically acceptable salts, can be used in the control or prevention of infectious diseases. Prepns. of approx. 250 example compds. and many intermediates are described, plus bioassay results for selected compds. against 3 organisms. For example, quinoline deriv. II [R7 = CHO] was condensed with PhNHCH2CH2CN in DMSO in the presence of KOBu-tert to give 98% II [R7 = PhNHCH:C(CN)CH2]. This was then cyclocondensed with guanidine-HCl in EtOH in the presence of KOBu-tert to give 44% title compd. III, which was isolated as the trifluoroacetate (IV). IV inhibited purified dihydrofolate reductase (DHFR) of Staphylococcus aureus ATCC 25923 and S. aureus 157/4696 with IC50 values of 0.0009 and 0.0500 .mu.M, resp., vs. 0.0340 .mu.M for trimethoprim. IV also had IC50 of 0.0190 .mu.M against DHFR of Pneumocystis carinii, vs. 43.0 .mu.M for trimethoprim.

IT **179940-19-3P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel benzylpyrimidines as antibacterials)

RN 179940-19-3 CAPLUS

CN 2-Propenoic acid, 3-[5-[5-[(2,4-diamino-5-pyrimidinyl)methyl]-2,3-dimethoxyphenyl]-2-furanyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **179940-41-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel benzylpyrimidines as antibacterials)
RN 179940-41-1 CAPLUS
CN 2-Propenoic acid, 3-[5-[5-[(2,4-diamino-5-pyrimidinyl)methyl]-2,3-dimethoxyphenyl]-2-furanyl]- (9CI) (CA INDEX NAME)



L28 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1995:520423 CAPLUS
DN 122:274041
TI thiophene compounds as antivirus, antiinflammatory, and immunoregulatory agents
IN Cho, Kintoku; Ryu, Manko; Chin, Kokubo; Hayashi, Funran; Go, Eisan
PA Ind Tech Res Inst, Japan
SO Jpn. Kokai Tokkyo Koho, 59 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 07002665	A2	19950106	JP 1991-218295	19910829

OS MARPAT 122:274041
AB Thiophene compds. or their pharmaceutically acceptable salts are useful as antivirus, antiinflammatory, and immunostimulant agents. These compds. can be isolated from plants such as Echinops grijsii or synthesized. As an example, bithiophene was prepd. by refluxing 2-iodothiophene in DMF at 153.degree. for 15 h. Biothiophene showed antiinflammatory activity in exptl. mice as detd. by the foot paw edema method.
IT **162691-96-5P 162691-97-6P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(plant or synthetic thiophene compds. as antivirus, antiinflammatory, and immunoregulatory agents)
RN 162691-96-5 CAPLUS
CN 2-Propen-1-one, 3-[2,2'-bithiophen]-5-yl-1-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 162691-97-6 CAPLUS
CN 2-Propen-1-one, 3-[2,2'-bithiophen]-5-yl-1-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



L28 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1994:41968 CAPLUS
DN 120:41968
TI Electrophotographic photoreceptor using stilbene or hydrazone compound as charge-transporting agent
IN Amano, Masayo; Kuroda, Masami; Kosho, Noboru
PA Fuji Electric Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05204175	A2	19930813	JP 1992-14380	19920130

GI



I



II



III

AB The photoreceptor comprises a substrate coated with a photosensitive layer contg. a stilbene compd. I or a hydrazone compd. II or III [R1-4, R7-10, R13-16 = (substituted) alkyl, aryl, heterocycle; R5-6, R11-12, R17-18 = H, alkyl, aryl; n = 1-3] as a charge-transporting agent. The photoreceptor shows high sensitivity and durability in repeated use.

IT **151703-30-9 151703-34-3 151703-46-7**
RL: USES (Uses)
(charge-transporting agent, for electrophotog. photoreceptor)

RN 151703-30-9 CAPLUS
CN 2,2'-Bifuran, 5-(2,2-diphenylethenyl)-5'-(2-methyl-1-propenyl)- (9CI) (CA INDEX NAME)



RN 151703-34-3 CAPLUS
CN 2,2':5',2''-Terfuran, 5-[2,2-bis(4-methylphenyl)ethenyl]-5''-(2-methyl-1-propenyl)- (9CI) (CA INDEX NAME)



RN 151703-46-7 CAPLUS
CN [2,2':5',2''-Terfuran]-5-carboxaldehyde, 5''-(2-methyl-1-propenyl)-, bis(4-methylphenyl)hydrazone (9CI) (CA INDEX NAME)



L28 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1992:173999 CAPLUS
DN 116:173999
TI Preparation of (carboxydihydroxyheptenyl)sulfonylpyrroles as HMG-CoA reductase inhibitors
IN Hirai, Kentaro; Ishiba, Teruyuki; Koike, Haruo; Watanabe, Nasamichi
PA Shionogi and Co., Ltd., Japan
SO Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 464845	A1	19920108	EP 1991-111221	19910705
	EP 464845	B1	19960605		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5128366	A	19920707	US 1991-707805	19910530
	JP 04352767	A2	19921207	JP 1991-157518	19910531
	JP 3068665	B2	20000724		
	CA 2046146	AA	19920106	CA 1991-2046146	19910703
	CA 2046146	C	19970225		
	AT 138909	E	19960615	AT 1991-111221	19910705
	ES 2090177	T3	19961016	ES 1991-111221	19910705

PRAI JP 1990-178564 19900705
OS MARPAT 116:173999
GI



I



II

AB Title compds. I [R1-R3 = H, (substituted) C1-6 alkyl, (substituted) aryl; R4 = (substituted) C1-6 alkyl, -aralkyl,-aryl,-heteroaryl; X = vinylene,

ethylene; Y = CH(OH)CH2CH(OH)CH2CO2R5, Q; R5 = H, C1-6 alkyl, aryl, aralkyl, pharmaceutically acceptable cation] were prepd. as HMG-CoA reductase inhibitors. Thus, 3-[4-(4-fluorophenyl)-2-isopropyl-1-(2-thienylsulfonyl)pyrrol-3-yl]-(E)-propenal (prepd. in 7 steps from Et isobutyrylacetate and 2-amino-4'-fluoroacetophenone) was condensed with AcCH2CO2Et and the product formed was subjected to borohydride redn. and hydrolysis of the resultant ester to give title compd. (E)-II. A no. of I had activities 1-4 times greater than Na mevinolin in in vitro HMG-CoA reductase inhibition tests.

IT **139993-88-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for HMG-CoA reductase inhibitors)

RN 139993-88-7 CAPLUS

CN 1H-Pyrrole, 4-(4-fluorophenyl)-2-(1-methylethyl)-3-(3-oxo-1-propenyl)-1-(2-thienylsulfonyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L28 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1991:570596 CAPLUS
DN 115:170596
TI Thienylvinylfuran nonlinear optical material
IN Suzuki, Yasushi; Sugiyama, Yoshio; Mitamura, Shuichi
PA Nippon Steel Corp., Japan; Nippon Steel Chemical Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03122624	A2	19910524	JP 1989-259941	19891006

OS MARPAT 115:170596
GI



I

AB A nonlinear optical furan deriv. I (R1 = alkyl; .gtoreq.1 of R2-3 = electron-attractive group, other is H) is claimed. The material is useful for laser wave length conversion, optical modulation, optical communication, etc.,. A room temp.-stable crystal I (R1 = Me, R2 = H, R3 = p-CCF3C6H4) was laser-irradiated to show strong 2nd harmonics.

IT **136428-36-9 136428-37-0 136428-38-1**
RL: TEM (Technical or engineered material use); USES (Uses)
(nonlinear optical material, with thermal stability)

RN 136428-36-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[5-[3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propenyl]-2-furanyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 136428-37-0 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[5-[3-(4-chlorophenyl)-3-oxo-1-propenyl]-2-furanyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 136428-38-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[5-[3-(1,3-benzodioxol-5-yl)-3-oxo-1-propenyl]-2-furanyl]-, methyl ester (9CI) (CA INDEX NAME)



L28 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1989:573977 CAPLUS
DN 111:173977
TI Preparation and formulation of 7-(butyl- or thienyl)-3,5-dihydroxy-6-heptenoate mevalonate analogs as anticholesteremics
IN Damon, Robert E., II; Wareing, James R.
PA Sandoz Pharmaceuticals Corp., USA
SO U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 816,664, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4829081	A	19890509	US 1986-945428	19861222
	AU 8665994	A1	19870519	AU 1986-65994	19861021
	AU 598775	B2	19900705		
	JP 63501153	T2	19880428	JP 1986-505883	19861021
	HU 48208	A2	19890529	HU 1986-5313	19861021
	FI 8702299	A	19870525	FI 1987-2299	19870525
	DK 8703218	A	19870624	DK 1987-3218	19870624
	US 4927851	A	19900522	US 1988-242667	19880912
PRAI	US 1986-816664	19860107			
	US 1985-791198	19851025			
	WO 1986-EP598	19861021			
	US 1986-945428	19861222			

OS MARPAT 111:173977
GI



I



II

AB The title compds. [I; R1-R3 = C1-6 alkyl not contg. an asym. C-atom, C3-7 cycloalkyl, (un)substituted Ph; R3 may addnl. = CR20:CR21R22; R20 = H, C1-3 alkyl; R21, R22 = H, C1-3 alkyl, Ph; X = S, O; Y = (E)-CH:CH, CH2CH2;
Z = CH(OH)CH2CH(OH)CH2CO2R14 or the hydroxypyranonyl group formed by lactonization thereof; R14 = H, a physiol. acceptable ester group or cation] were prepd. 4-FC6H4CH(OH)CHPhSH (prepn. given) was stirred 4 h with Me2CHCH:C(CO2Et)P(O)(OEt)2 (prepn. given) in THF to give, after Swern
oxidn. of the product, 4-FC6H4COCHPhSCH(CHMe2)CH(CO2Et)P(O)(OEt)2 which was stirred 1 h with (Me2CH)2NLi in THF to give, after dicyanobenzoquinone
oxidn. of the product, thiophenecarboxylate II (R = CO2Et, R3 = Ph). The latter was converted in 2 steps to II (R = CHO, R3 = Ph) which was added to a soln. of cis-BrCH:CHOEt in THF which was stirred 2 h at -78.degree.

with Me3CLi to give, after 10 min addnl. stirring, II (R = CH:CHCHO, R3 = Ph) which was stirred 1 h at -20.degree. with MeCOCH2CO2Et in THF which had been treated with BuLi to give, after borane redn. of the product, II [R = CH:CHCH(OH)CH2CH(OH)CO2Et, R3 = Ph]. II [R = CH:CHCH(OH)CH2CH(OH)CO2Na, R3 = CHMe2) (III) had EC50 of 0.076 mg/kg orally for inhibition of cholesterol biosynthesis in rats. Capsules were prepd. each contg. III 0.5, starch 248.5, and Mg stearate 1 mg.

IT **113070-86-3P 113070-96-5P 123094-03-1P**
123094-04-2P 123094-05-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, in prepn. of anticholesteremics)

RN 113070-86-3 CAPLUS
CN 2-Propenal, 3-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-5-phenyl-3-furanyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 113070-96-5 CAPLUS
CN 2-Propenal, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-thienyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 123094-03-1 CAPLUS
CN 2-Propenoic acid, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-furanyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 123094-04-2 CAPLUS
CN 2-Propen-1-ol,
3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-furanyl]-
, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 123094-05-3 CAPLUS
CN 2-Propenal, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-furanyl]-,
(E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **123094-23-5P 123094-36-0P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as anticholesteremic)
RN 123094-23-5 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-(2-methyl-1-propenyl)-3-thienyl]-3,5-dihydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 123094-36-0 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-(2-methyl-1-propenyl)-3-thienyl]-3,5-dihydroxy-, monosodium salt (9CI) (CA INDEX NAME)



L28 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1989:173074 CAPLUS
DN 110:173074
TI Preparation of substituted furans as inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase
IN Fobare, William F.; Strike, Donald P.
PA American Home Products Corp., USA
SO U.S., 7 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4792614	A	19881220	US 1987-82013	19870805

OS MARPAT 110:173074
GI



AB The title compds. [I; R1 = CH:CHCH(OH)CH2CH(OH)CH2CO2R (Q), .delta.-lactone moiety Q1; R = H, C1-4 alkyl; 1 of R2, R3 = (un)substituted Ph, the other = H, C1-8 alkyl, halo] and their pharmaceutically acceptable salts were prepd. as inhibitors of hydroxymethylglutaryl CoA (HMG-CoA), and thus useful as anticholesteremics. 4-FC6H4COCH2Cl underwent Grignard reaction with BrMgCH2C.tplbond.CH to give 4-FC6H4C(CH2Cl)(OH)CH2C.tplbond.CH which was cyclized by stirring in Et2N with powd. NaOH to give 4,5-epoxy-4-(4-fluorophenyl)-1-pentyne. The latter was treated with HgSO4 in aq. H2SO4 to give I (R1 = H, R2 = 4-FC6H4, R3 = Me) which was successively condensed with Me2NCH:CHCHO in the presence of POCl3, and with MeCOCH2CO2Me dianion at -78.degree. in THF, and reduced with NaBH4/BMe3 in MeOH/THF to give (3S, 5S, E)-I (R1 = Q, R = Me, R2 = 4-FC6H4, R3 = Me) (II). II inhibited HMG-CoA from rat liver microsomes with an IC50 of 62.0 .mu.M.

IT **119969-28-7P 119969-30-1P 119969-34-5P**
119969-39-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and condensation of, with acetoacetate dianion)

RN 119969-28-7 CAPLUS
CN 2-Propenal, 3-[3-(4-fluorophenyl)-5-methyl-2-furanyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 119969-30-1 CAPLUS
CN 2-Propenal, 3-(5-methyl-3-phenyl-2-furanyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 119969-34-5 CAPLUS
CN 2-Propenal, 3-[3-(4-fluorophenyl)-2-furanyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 119969-39-0 CAPLUS
CN 2-Propenal, 3-[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **119969-37-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydride redn. of)
RN 119969-37-8 CAPLUS
CN 2-Propenoic acid, 3-[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **119969-38-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidn. of)
RN 119969-38-9 CAPLUS
CN 2-Propen-1-ol, 3-[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L28 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1988:630987 CAPLUS
DN 109:230987
TI Preparation of 6-chloro-2-(nitrophenyl)thieno(3,2-b)furan-5-carboxylic acid chloride
IN Kralovicova, Eva; Krutosikova, Alzbeta; Kovac, Jaroslav
PA Czech.
SO Czech., 3 pp.
CODEN: CZXXA9
DT **Patent**
LA Slovak
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CS 249490	B1	19870312	CS 1985-7054	19851001

AB Stirring 2.59 g 3-[5-(2-nitrophenyl)-2-furyl]acrylic acid with 2.27 g PhCH2N+Et3 Cl- in 6.4 g SOCl2 at 135.degree., feeding an addnl. 2.2 g SOCl2, stirring 2 h, evapg. SOCl2, and extg. the product with C6H6 gave 23.4% title compd.
IT **58110-36-4**
RL: RCT (Reactant)
(cyclization of)
RN 58110-36-4 CAPLUS
CN 2-Propenoic acid, 3-[5-(2-nitrophenyl)-2-furanyl]- (9CI) (CA INDEX NAME)



L28 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1988:112221 CAPLUS
DN 108:112221
TI Preparation of (heterocyclylalkenyl)mevalonates as hypolipemics and antiatherosclerotic agents
IN Wareing, James Richard; Damon, Robert Edson
PA Sandoz A.-G., Switz.; Sandoz-Patent-G.m.b.H.; Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H.
SO Eur. Pat. Appl., 41 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 221025	A1	19870506	EP 1986-810470	19861021
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
WO 8702662	A2	19870507	WO 1986-EP598	19861021
WO 8702662	A3	19871217		
W: AU, DK, FI, HU, JP, KR				
AU 8665994	A1	19870519	AU 1986-65994	19861021
AU 598775	B2	19900705		
JP 63501153	T2	19880428	JP 1986-505883	19861021
HU 48208	A2	19890529	HU 1986-5313	19861021
IL 80403	A1	19900917	IL 1986-80403	19861023
CA 1278794	A1	19910108	CA 1986-521333	19861024
PL 154130	B1	19910731	PL 1986-262032	19861024
FI 8702299	A	19870525	FI 1987-2299	19870525
DK 8703218	A	19870624	DK 1987-3218	19870624

PRAI US 1985-791198 19851025
US 1986-816664 19860107
WO 1986-EP598 19861021
GI



I



II



III

AB The title compds. [I, II; R1,R2 = alkyl, cycloalkyl, (un)substituted Ph; R3 = R4, alkenyl; R4 = H, R1; X = (CH2)m, alkenylene; Y = NR4, O, S; Z = CHOHCH2CR5OHCH2CO2H; R5 = H, alkyl; m = 0-3] were prepd. as hypolipemics

and antiatherosclerotic agents (no data). PhCOCH2CH(CHMe2)COCO2Et (prepn.
given) and 4-FC6H4NH2 were refluxed 16 h in PhMe contg. TiCl4 to give III (R = CO2Et) which was converted in 7 steps to (.+-.)-erythro-III (R = CH:CHCHOHCH2CHOHCH2CO2Et).

IT **113070-86-3P 113070-93-2P 113070-96-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and condensation of, in prepn. of hypolipemic and antiatherosclerotic agents)

RN 113070-86-3 CAPLUS
CN 2-Propenal, 3-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-5-phenyl-3-furanyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 113070-93-2 CAPLUS
CN 2-Propenal, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-furanyl]- (9CI) (CA INDEX NAME)



RN 113070-96-5 CAPLUS
CN 2-Propenal, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-thienyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **113070-92-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidn. of, in prepn. of hypolipemic and antiatherosclerotic agents)
RN 113070-92-1 CAPLUS
CN 2-Propen-1-ol, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-furanyl]- (9CI) (CA INDEX NAME)



IT **113070-90-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and redn. of, in prepn. of hypolipemic and antiatherosclerotic agents)
RN 113070-90-9 CAPLUS
CN 2-Propenoic acid, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-furanyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT **113071-38-8P 113071-39-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as hypolipemic and antiatherosclerotic agent)
RN 113071-38-8 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-(2-methyl-1-propenyl)-3-thienyl]-3,5-dihydroxy-, ethyl ester, [R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 113071-39-9 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-(2-methyl-1-propenyl)-3-thienyl]-3,5-dihydroxy-, monosodium salt, [R*,S*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



L28 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1986:168825 CAPLUS
DN 104:168825
TI Glutamic acid diamide derivatives and their use as antiulcer agents
PA Toyama Chemical Co., Ltd. , Japan
SO Belg., 77 pp.
CODEN: BEXXAL
DT **Patent**
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 901229	A1	19850606	BE 1984-214130	19841206
	JP 61001651	A2	19860107	JP 1984-120584	19840612
	JP 04066230	B4	19921022		
	DK 8405636	A	19851213	DK 1984-5636	19841128
	DK 168005	B1	19940117		
	GB 2160197	A1	19851218	GB 1984-30081	19841128
	GB 2160197	B2	19880217		
	CA 1265801	A1	19900213	CA 1984-468866	19841128
	DE 3444046	A1	19851212	DE 1984-3444046	19841203
	DE 3444046	C2	19901129		
	US 4610983	A	19860909	US 1984-677466	19841203
	SE 8406141	A	19851213	SE 1984-6141	19841204
	SE 456161	B	19880912		
	FR 2565587	A1	19851213	FR 1984-18609	19841206
	FR 2565587	B1	19890317		
	NL 8403716	A	19860102	NL 1984-3716	19841206
	NL 193022	B	19980401		
	NL 193022	C	19980804		
	ES 538349	A1	19860316	ES 1984-538349	19841206
	CH 663019	A	19871113	CH 1984-5803	19841206
	FI 8404852	A	19851213	FI 1984-4852	19841207
	FI 81563	B	19900731		
	FI 81563	C	19901112		
	AU 8436398	A1	19851219	AU 1984-36398	19841207
	AU 556097	B2	19861023		
	ES 548220	A1	19861216	ES 1985-548220	19851025
	ES 548221	A1	19861216	ES 1985-548221	19851025
	ES 548222	A1	19861216	ES 1985-548222	19851025

PRAI JP 1984-120584 19840612
GI



I

AB Amino acid diamides R1R2NCO(CH2)nCH(NHCOZ1R5)CONR3R4 (R1, R2, R3, and R4 =
H, alkyl, cycloalkyl, alkenyl, aralkyl; NR1R2 or NR3R4 form a heterocycle;

n = 1, 2, 3; Z1 = direct bond, alkylene, alkadienylene; R5 = cycloalkyl, acyl, heterocyclic group)were prepd. and they showed anti-ulcer activity. Thus, H-DL-Glu(NHMe)-NPr2.HCl was condensed with 3-(2-furyl)acrylic acid by ClCO2Et in the presence of Et3N to give DL-glutamic acid diamide I.

IT **100679-37-6P 100679-38-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as anti-ulcer agent)

RN 100679-37-6 CAPLUS
CN Pentanediamide, N5,N5-dimethyl-2-[[1-oxo-3-(5-phenyl-2-furanyl)-2-propenyl]amino]-N1,N1-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 100679-38-7 CAPLUS
CN Pentanediamide, 2-[[3-[5-(4-chlorophenyl)-2-furanyl]-1-oxo-2-propenyl]amino]-N5,N5-dimethyl-N1,N1-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L28 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1985:422927 CAPLUS
DN 103:22927
TI N-Acyl acidic amino acid diamides
PA Toyama Chemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 59227847	A2	19841221	JP 1983-101711	19830609
	JP 04060983	B4	19920929		

AB One hundred title compds. RR1NCO(CH2)nCH(CONR2R3)NHCOZR4 [I; R, R1, R2, R3 = H, (un)substituted alkyl; RR1N or R2R3N may form a heterocyclic ring; Z = bond, alkylene, alkenylene, alkadienylene; n = 1-3] were prepd. by, e.g., reaction of RR1NCO(CH2)nCH(CONR2R3)NH2 (II) with R4ZCO2H (III) or their CO2H reactive derivs. Anti-ulceric activity data of I were shown to be more potent than proglumide. Thus, 3 g DL-II.HCl (R = Me, R1 = H, R2 = R3 = Pr, n = 2) was added to a mixt. of III (R4 = furyl, Z = CH:CH) 1.5, Et3N 2.7, and ClCO2Et 1.3 g in CH2Cl2 at -25.degree. to -20.degree. to give, after 1 h, 80% DL-I (R = Me, R1 = H, R2 = R3 = Pr, n = 2, R4 = furyl, Z = CH:CH).

IT **96785-17-0P 96785-18-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 96785-17-0 CAPLUS
CN Pentanediamide, N5,N5-dimethyl-2-[[1-oxo-3-(5-phenyl-2-furanyl)-2-propenyl]amino]-N1,N1-dipropyl- (9CI) (CA INDEX NAME)



RN 96785-18-1 CAPLUS
CN Pentanediamide, 2-[[3-[5-(4-chlorophenyl)-2-furanyl]-1-oxo-2-propenyl]amino]-N5,N5-dimethyl-N1,N1-dipropyl- (9CI) (CA INDEX NAME)


(n-Pr)2N
O
Me2N
O
N
H
O
O
Cl

L28 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1985:45699 CAPLUS
DN 102:45699
TI Penem derivatives and precursors
IN Osborne, Neal Frederick
PA Beecham Group PLC, UK
SO Eur. Pat. Appl., 133 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 120613	A1	19841003	EP 1984-301255	19840227
	R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
	ZA 8401514	A	19850130	ZA 1984-1514	19840229
	ES 530153	A1	19860401	ES 1984-530153	19840229
	AU 8425189	A1	19840906	AU 1984-25189	19840301
	AU 568119	B2	19871217		
	JP 60001182	A2	19850107	JP 1984-41200	19840302
	ES 537350	A1	19850816	ES 1984-537350	19841102
	ES 537351	A1	19851216	ES 1984-537351	19841102
PRAI	GB 1983-5704	19830302			
	GB 1983-30516	19831116			

GI



I



II



III

AB Penems I [R = (un)substituted furyl, thienyl, pyrrolyl; R1 = H, org.] were prepd. Thus 1-tert-butyldimethylsilyl-4-tritylthio-2-azetidinone was treated with furfural to give II (R2 = H, R3 = SiMe2CMe3) which was acetylated, desilylated, and treated with HCOCO2CH2C6H4NO2-4 to give II [R2 = Ac, R3 = CH(OH)CO2CH2C6H4NO2-4]. Chlorination of the latter compd. and treatment with PPh3 gave II [R2 = Ac, R3 = C(:PPh3)CO2CH2C6H4NO2-4] which was converted to the Ag thiolate and cyclized to give III. Elimination of HOAc from III, with 1,8-diazabicyclo[5.4.0]undec-7-ene and hydrogenolysis gave (Z)-I Na salt (R = 2-furyl, R1 = H) which had a min. inhibitory concn. against Staphylococcus aureus Russell of 16.0 .mu.g/mL and was synergistic with amoxycillin.

IT **93856-01-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. and ring closure of)

RN 93856-01-0 CAPLUS

CN Silver, [(4-nitrophenyl)methyl 3-[(acetyloxy)[5-(3-methoxy-3-oxo-1-propenyl)-2-furanyl]methyl]-2-mercapto-4-oxo-.alpha.-(triphenylphosphoranylidene)-1-azetidineacetato]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L28 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1984:571101 CAPLUS
DN 101:171101
TI 4-Oxo-1,4-dihydronicotinic acid derivatives and their salts and their antibacterial use
IN Narita, Hirokazu; Konishi, Yoshinori; Nitta, Jun; Misumi, Shunjiro; Nagaki, Hideyoshi; Kitayama, Isao; Nagai, Yoriko; Watanabe, Yasuo; Matsubara, Nobuyuki; et al.
PA Toyama Chemical Co., Ltd. , Japan
SO Ger. Offen., 171 pp.
CODEN: GWXXBX
DT **Patent**
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3338846	A1	19840503	DE 1983-3338846	19831026
	DE 3338846	C2	19900913		
	JP 59080665	A2	19840510	JP 1982-188930	19821029
	JP 02061947	B4	19901221		
	JP 60089472	A2	19850520	JP 1983-197624	19831024
	JP 06006575	B4	19940126		
	DK 8304930	A	19840430	DK 1983-4930	19831027
	DK 160421	B	19910311		
	DK 160421	C	19910909		
	GB 2130580	A1	19840606	GB 1983-28784	19831027
	GB 2130580	B2	19860129		
	US 4698352	A	19871006	US 1983-546165	19831027
	BE 898123	A1	19840430	BE 1983-211799	19831028
	SE 8305950	A	19840430	SE 1983-5950	19831028
	SE 455092	B	19880620		
	SE 455092	C	19880929		
	FR 2535320	A1	19840504	FR 1983-17355	19831028
	FR 2535320	B1	19870220		
	ES 526903	A1	19851201	ES 1983-526903	19831028
	CH 661505	A	19870731	CH 1983-5853	19831028
	CA 1326023	A1	19940111	CA 1983-440006	19831028
	JP 06234742	A2	19940823	JP 1993-176266	19930623
	JP 07002715	B4	19950118		
PRAI	JP 1982-188930	19821029			
	JP 1983-197624	19831024			

GI



I



II

AB The title compds. I [R = H, a protective group; R1 = substituted aryl, (un)substituted heterocyclyl; R2 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, acyl, aryl, heterocyclyl] (>280 compds.) were prepd. Thus, 4-ClC6H4CH:CHCOCH2CO2Me was condensed with 4-FC6H4NH2 and Me2NCH(OMe)2 to give 4-ClC6H4CH:CHCOC(CO2Me):CHNHC6H4F-4, which was cyclized by heating at 140.degree. in DMF to give tetrahydronicotinate II. II was dehydrogenated by heating in C6H6 with 2,3-dichloro-5,6-dicyano-p-benzoquinone and sapond. to give I (R = H, R1 = 4-FC6H4, R2 = 4-ClC6H4) (III). I are effective against a variety of bacterial strains. III had a min. inhibitory concn. against Staphylococcus aureus FDA209P of 6.23 mcg/mL.

IT **92362-83-9 92364-24-4**
RL: RCT (Reactant)
(aminomethylenation of)

RN 92362-83-9 CAPLUS

CN 4-Pentenoic acid, 3-oxo-5-(5-phenyl-2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 92364-24-4 CAPLUS

CN 4-Pentenoic acid, 5-[3-(4-nitrophenyl)-2-thienyl]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT **92362-74-8P 92363-52-5P 92363-53-6P**
92364-16-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)
RN 92362-74-8 CAPLUS
CN 4-Pentenoic acid,
2-[[(4-hydroxyphenyl)amino]methylene]-3-oxo-5-(5-phenyl-
2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 92363-52-5 CAPLUS
CN 4-Pentenoic acid, 3-oxo-5-(5-phenyl-2-thienyl)-2-[(4-
pyridinylamino)methylene]-, methyl ester (9CI) (CA INDEX NAME)



RN 92363-53-6 CAPLUS
CN 4-Pentenoic acid, 2-[[(4-hydroxyphenyl)amino]methylene]-3-oxo-5-[5-(2-pyridinyl)-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 92364-16-4 CAPLUS
CN 4-Pentenoic acid, 2-[[(4-fluorophenyl)amino]methylene]-5-[3-(4-nitrophenyl)-2-thienyl]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



L28 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1977:527659 CAPLUS
DN 87:127659
TI Treating inflammation with trans-5-(4-chlorophenyl)-2-furanacrylic acid
IN Goldenberg, Marvin M.
PA Morton-Norwich Products, Inc., USA
SO U.S., 2 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4036981	A	19770719	US 1976-704122	19760712

GI



I

AB A method of healing inflammation involves oral administration of trans-5-(4-chlorophenyl)-2-furanacrylic acid (I) [**62806-34-2**]. Thus, oral administration of 300 mg I/kg to rats caused 77.5% and 74.6% inhibition of carrageenan-induced edema at 4 and 6 h, resp., after administration. No untoward pharmacol. effects were obsd. at this dose.

IT **62806-34-2**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(inflammation-inhibitory activity of)

RN 62806-34-2 CAPLUS
CN 2-Propenoic acid, 3-[5-(4-chlorophenyl)-2-furanyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L28 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1976:135452 CAPLUS
DN 84:135452
TI Furan derivatives
IN Yoshina, Shigetaka
PA Japan
SO Japan. Kokai, 5 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 50121261	A2	19750923	JP 1974-28299	19740312

GI



I, Z=O
II, Z=NNHC(:NH)NH$_2$

AB 3,4-Diphenylfurans I (R1 = H, alkyl, alkoxy; m, n = 0, 1; R2 = alkyl, aryl, CO2H, CO2Et, furyl) were treated with aminoguanidine to give II.
II
are antitubercular, fungicidal and protozoacidal agents (no data). Thus, 1 g 3,4-diphenyl-2-acetofuran, 0.5 g aminoguanidine carbonate, 1 ml concd.
HCl and EtOH was refluxed 1 hr to give 0.3 g II (R1 = H, m = n = 0, R2 = Me). Similarly prepd. were II (R1, m, n, R2 given): H, 1, 1, 2-furyl; H, 1, 0, CO2H; 4-MeO, 0, 0, Me; 4-Me, 0, 0, Me.

IT **57386-07-9P 57386-08-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction with aminoguanidine)

RN 57386-07-9 CAPLUS
CN 3-Buten-2-one, 4-(3,4-diphenyl-2-furanyl)- (9CI) (CA INDEX NAME)



RN 57386-08-0 CAPLUS
CN 3-Butenoic acid, 4-(3,4-diphenyl-2-furanyl)-2-oxo- (9CI) (CA INDEX NAME)



IT **58849-08-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 58849-08-4 CAPLUS
CN 3-Butenoic acid, 4-[3,4-bis(4-methoxyphenyl)-2-furanyl]-2-oxo- (9CI) (CA INDEX NAME)



IT **57386-12-6 57386-13-7 57386-16-0**
57386-19-3 57386-23-9
RL: RCT (Reactant)
(reaction of, with aminoguanidine)
RN 57386-12-6 CAPLUS
CN 1,4-Pentadien-3-one, 1-(3,4-diphenyl-2-furanyl)-5-phenyl- (9CI) (CA INDEX
NAME)



RN 57386-13-7 CAPLUS
CN 1,4-Pentadien-3-one, 1-(3,4-diphenyl-2-furanyl)-5-(4-methoxyphenyl)-
(9CI)
(CA INDEX NAME)



RN 57386-16-0 CAPLUS
CN 1,4-Pentadien-3-one, 1-(3,4-diphenyl-2-furanyl)-5-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 57386-19-3 CAPLUS
CN 1,4-Pentadien-3-one, 1-(3,4-diphenyl-2-furanyl)-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 57386-23-9 CAPLUS
CN 3-Butenoic acid, 4-(3,4-diphenyl-2-furanyl)-2-oxo-, ethyl ester (9CI) (CA
INDEX NAME)



L28 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1976:90187 CAPLUS
DN 84:90187
TI Triazine derivatives
IN Yoshina, Shigetaka
PA Japan
SO Japan. Kokai, 3 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50121289	A2	19750923	JP 1974-28298	19740312

GI For diagram(s), see printed CA Issue.
AB Triazines I (R1 = H, OH) and their salts were prepd. by heating aminoguanidines II (R = alkoxycarbonyl, p-ON2C6H4CH:CH) or their salts.
I
had antibacterial and protozoacidal activities (no data). Thus, a mixt. of 1 g II.cntdot.HCl (R = p-ON2C6H4CH:CH) (III) and 0.2 g NaHCO3 in DMF was heated 1.5 hr to 130.degree. and 0.5 hr at 130.degree. to give 0.5 g
I
(R1 = H). I (R1 = OH) was also prepd. 3,4-Diphenyl-2-furfural (10 g), 200 ml acetone and H2O was treated with 33% aq. NaOH 4 hr at room temp.
to
give 4.5 g 3,4-diphenyl-2-furfurylideneacetone, which (1 g) in 50% aq. EtOH was treated with 0.4 g 4-O2NC6H4CHO and 1 ml 10% NaOH 4 hr at room temp. to give 0.9 g 1-(3,4-diphenyl-2-furyl)-5-(4-nitrophenyl)-1,4-pentadien-3-one, which (1.7 g) was refluxed with 0.5 g aminoguanidine bicarbonate in EtOH and 1 ml HCl to give 1.7 g III.

IT **57386-08-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and esterification of)
RN 57386-08-0 CAPLUS
CN 3-Butenoic acid, 4-(3,4-diphenyl-2-furanyl)-2-oxo- (9CI) (CA INDEX NAME)



IT **57386-19-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction with aminoguanidine bicarbonate)
RN 57386-19-3 CAPLUS
CN 1,4-Pentadien-3-one, 1-(3,4-diphenyl-2-furanyl)-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



IT **57386-23-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction with aminoguanidine carbonate)
RN 57386-23-9 CAPLUS
CN 3-Butenoic acid, 4-(3,4-diphenyl-2-furanyl)-2-oxo-, ethyl ester (9CI)
(CA
INDEX NAME)



IT **57386-07-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction with benzaldehyde)
RN 57386-07-9 CAPLUS
CN 3-Buten-2-one, 4-(3,4-diphenyl-2-furanyl)- (9CI) (CA INDEX NAME)



L28 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2001 ACS
AN 1974:120741 CAPLUS
DN 80:120741
TI Diphenylfurans
IN Yoshina, Shigetaka
SO Japan. Kokai, 7 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48091055	A2	19731127	JP 1972-24859	19720310

GI For diagram(s), see printed CA Issue.
AB The bactericidal and fungicidal title compds. (I R1, R2 = H, alkyl, alkoxy; R3 = H or NO2; n = 0 or 1; R4 = H, substituted amino, quinolyl, substituted quinolyl, aryl, C(:NH)NH, etc.) were prepd. by treating aldehydes (II) with amines. E.g., 1 g II (R1 = R2 = p-OMe, R3 = H, n = 0) in EtOH was refluxed 30 min with 0.36 g NH2CONHNH2.HCl to give 1 g I (R4 = NHCONH2, the other symbols the same as before). Similarly prepd. were the following I (R1, R2, R3, R4, and n given): H, H, H, NHCONH2, 0; H, H, H, NHCONH2, 1; p-OMe, p-OMe, H, OH, 0; H, H, NO2, NHC(:NH)NHi, 0; H, H, NO2, 3-quinolyl, 0.
IT **52101-43-6**
RL: RCT (Reactant)
(reaction of, with semicarbazide)
RN 52101-43-6 CAPLUS
CN 2-Propenal, 3-(3,4-diphenyl-2-furanyl)- (9CI) (CA INDEX NAME)